Literature DB >> 29182162

Melanoma in 2017: Moving treatments earlier to move further forwards.

Michael A Davies1, Keith T Flaherty2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29182162      PMCID： PMC7436336          DOI： 10.1038/nrclinonc.2017.183

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Cyril Konto; Axel Hoos; Veerle de Pril; Ravichandra Karra Gurunath; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  Lancet Oncol       Date:  2015-03-31       Impact factor: 41.316

2.  Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Authors:  Mark B Faries; John F Thompson; Alistair J Cochran; Robert H Andtbacka; Nicola Mozzillo; Jonathan S Zager; Tiina Jahkola; Tawnya L Bowles; Alessandro Testori; Peter D Beitsch; Harald J Hoekstra; Marc Moncrieff; Christian Ingvar; Michel W J M Wouters; Michael S Sabel; Edward A Levine; Doreen Agnese; Michael Henderson; Reinhard Dummer; Carlo R Rossi; Rogerio I Neves; Steven D Trocha; Frances Wright; David R Byrd; Maurice Matter; Eddy Hsueh; Alastair MacKenzie-Ross; Douglas B Johnson; Patrick Terheyden; Adam C Berger; Tara L Huston; Jeffrey D Wayne; B Mark Smithers; Heather B Neuman; Schlomo Schneebaum; Jeffrey E Gershenwald; Charlotte E Ariyan; Darius C Desai; Lisa Jacobs; Kelly M McMasters; Anja Gesierich; Peter Hersey; Steven D Bines; John M Kane; Richard J Barth; Gregory McKinnon; Jeffrey M Farma; Erwin Schultz; Sergi Vidal-Sicart; Richard A Hoefer; James M Lewis; Randall Scheri; Mark C Kelley; Omgo E Nieweg; R Dirk Noyes; Dave S B Hoon; He-Jing Wang; David A Elashoff; Robert M Elashoff
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

3.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

Review 4.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

5.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

6.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

7.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Authors:  Georgina V Long; Axel Hauschild; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Dirk Schadendorf; Thierry Lesimple; Ruth Plummer; Ran Ji; Pingkuan Zhang; Bijoyesh Mookerjee; Jeff Legos; Richard Kefford; Reinhard Dummer; John M Kirkwood
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

8.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

9.  Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson
Journal:  CA Cancer J Clin       Date:  2017-10-13       Impact factor: 508.702
  9 in total
  2 in total

1.  Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients.

Authors:  Biao Huang; Wei Han; Zu-Feng Sheng; Guo-Liang Shen
Journal:  Cancer Cell Int       Date:  2020-05-25       Impact factor: 5.722

Review 2.  Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance.

Authors:  Francesca Mo; Alessia Pellerino; Riccardo Soffietti; Roberta Rudà
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.